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Determination of Ceftiofur and its Metabolites in Plasma Using Reverse
Phase Liquid Chromatography
Sherry Cox, Molly White, Kristen Gordon, Joan Bailey, University of Tennessee College of Veterinary Medicine, Department of Biomedical & Diagnostic Sciences, Knoxville, TN 37996

ABSTRACT
A high performance liquid chromatography procedure for the
determination of ceftiofur and all its desfuroylceftiofur metabolites in plasma
has been developed and validated using reverse phase liquid
chromatography. Following a derivatization method that converts ceftiofur
and all desfuroylceftiofur metabolites to desfuroylceftiofur acetamide,
separation was attained on a Symmetry C18 column and quantification
occurred using UV detection at 265 nm. The mobile phase was a mixture of
(A) 0.1% trifluroracetic acid (TFA) in water and (B) 0.1% TFA in acetonitrile.
The mixture was pumped at a starting gradient of 90% A and 10% B and was
adjusted to 75% A and 25% B over 25 min, and back to initial conditions over
3 min. with a flow-rate of 1.0 ml/min. The procedure produced a linear curve
over the concentration range of 0.1 – 100 µg/mL with a lower limit of
quantification of 0.1 µg/mL. Intra-assay variability ranged from 0.7 to 4.5%
and inter-assay variability ranged from 3.6 to 8.8% for desfuroylceftiofur
acetamide, respectively, and the average recovery was 99%. This method
could be useful to those investigators dealing with small sample volumes,
particularly when conducting pharmacokinetics studies which require
multiple sampling from the same animal.

INTRODUCTION
Ceftiofur is a broad spectrum, third-generation cephalosporin antibiotic
used in a variety of gram-positive, gram-negative, and anaerobic infections in
domestic animal species including many species of Pasterurella, spp.,
Streptococcus spp., Staphylococcus spp., Salmonella spp., and Escherichia
coli. Ceftiofur is cleaved into furoic acid and desfuroylceftiofur, an active
metabolite. Like most cephalosporin’s, it is bactericidal and acts by inhibiting
cell wall synthesis. The sodium salt of ceftiofur is approved for use in the US
for a variety of domestic species including cattle, swine, sheep, goats, horses,
dogs, and poultry. The hydrochloride salt of ceftiofur is approved for use in
cattle and swine. Ceftiofur crystalline-free acid (CCFA, Excede) is a long-acting
preparation of ceftiofur labeled for use as a single dose in cattle and swine
for treatment of certain bacterial pathogens. CCFA is also labeled for
treatment of lower respiratory infections in horses and is used off label in
many non-domestic species, including birds kept as companion animals or in
zoological collections.

MATERIALS AND METHODS
Reagents and Standards
Ceftiofur and cefotaxime were purchased from U.S. Pharmacopeia. All
other regent grade chemicals and solvents were purchased from Fisher
Scientific. Stock solutions of ceftiofur and cefotaxime (100 µg/ml) were
prepared in methanol. Dilutions in methanol were prepared to produce 1 and
10 µg/ml working stocks. The standards were stored at 4° C and were stable
for a minimum of 6 months. For preparation of calibration standards and
quality control samples, appropriate aliquots of the working stock solutions
were added to untreated plasma. The final concentrations were 0.1, 0.25,
0.5, 1, 2.5, 5, 10, 25, 50, and 100 µg/ml for calibration standards and 0.35,
3.5, 35 and 75 µg/ml quality control samples. Calibration standards and
control samples were treated the same as test samples. Linearity was
assessed by linear regression analysis. The calibration curve had to have a
correlation coefficient of 0.99 or better. The acceptance criterion for each
back calculated standard concentration was 15% deviation from the nominal
value except lower limit of quantification (LLOQ), which was set at 20%.

Figure 1
A: Blank calf plasma sample

Chromatographic conditions
The system consisted of a 2695 separations module and a 2487 UV detector (Waters).
Separation was attained on a Symmetry C18 column (4.6 x 250 mm, 5 µm) with a
Symmetry guard column. The mobile phase was a mixture of (A) 0.1% trifluroracetic
acid (TFA) in water and (B) 0.1% TFA in acetonitrile. The mixture was pumped at a
starting gradient of 90% A and 10% B and was adjusted to 75% A and 25% B over 25
min, and back to initial conditions over 3 min. The drug was quantified using UV
detection at 265 nm and the flow rate was 1.0 ml/min.

Sample Treatment
B: Spiked 5 µg/ml standard in calf plasma

C: Calf plasma sample 4 h after CCFA administration

Ceftiofur was extracted from plasma samples using a derivatization method that
converts ceftiofur and all desfuroylceftiofur metabolites to desfuroylceftiofur
acetamide. Previously frozen plasma samples were thawed and vortexed and 100 µl
were transferred to a clean test tube then 15 µl of internal standard (100 µg/ml
cefotaxime) added. Seven milliliters of 0.4 % dithioerythritol in borate buffer was
added then tubes were placed in a 50˚ C water bath for 15 min. The tubes were
removed and allowed to cool to room temperature then 1.5 ml of iodoacetaminde
buffer was added. The solution was then passed through a prewet Oasis HLB extraction
column. Samples were eluted with a 5% glacial acetic acid in methanol which was then
evaporated to dryness with nitrogen gas. Samples were reconstituted in 200 µl of
mobile phase and 50 µl were injected into the HPLC system.

RESULTS AND DISCUSSION

Table 1. Intra-assay accuracy and precision for ceftiofur in
plasma. (n=5)

SD: standard deviation; n: number of samples; CV: coefficient of variation

Table 2. Inter-assay variability and recovery for ceftiofur in
plasma. (n=5)

Blank plasma samples were prepared in the same manner as study samples and no
endogenous plasma components interfered with the elution of the peaks of interest.
Fig. 1 shows chromatograms of a (A) blank plasma sample, (B) a 5 µg/ml spiked calf
plasma standard and (C) a calf plasma sample 4 hours after administration of a 6.6
mg/kg subcutaneous dose of ceftiofur. Retention times were 11.97 min for ceftiofur
and 17.15 min for cefotaxime. For specificity testing six different blank plasma samples
were used in the pre-validation process.
The plasma peak ratio (area of ceftiofur divided by the IS area) versus the
concentration was plotted and produced a linear curve, over the concentration range of
0.1 – 100 µg/ml, with resulting correlation coefficients of >0.999. A typical equation for
the calibration curve was y = 0.0939x + -0.669, where y represents the peak area ratios
of ceftiofur to internal standard and x represents the plasma concentration of ceftiofur
in µg/mL. Intra and inter-assay RSD for plasma spiked with specific concentrations of
ceftiofur ranges from 0.7 to 7.7% (Tables 1 and 2). The precision was below the set ±
15% for all quality control samples.
The recovery (Table 2) for ceftiofur from spiked plasma was determined by comparing
extracted areas with directly injected analyte areas and ranged from 95% to 104%. The
relative standard deviation was less than 10% for all values. The recovery of cefotaxime
was 98% and its relative standard deviation was 3.3%. The addition of cefotaxime as an
internal standard corrects for intra- and inter-day assay variability in the assay. The
lower limit of quantification (LOQ) was 0.1 µg/ml and represents a peak approximately
five times baseline noise.

CONCLUSIONS

SD: standard deviation; n: number of days; CV: coefficient of variation

In conclusion, this analytical procedure was validated in terms of recovery, linearity,
LLOQ, precision, and accuracy. The limit of quantification and recovery are more than
adequate for use in pharmacokinetic studies. Our results indicate that this HPLC
procedure is a reproducible method that provides consistent quantification of ceftiofur
and all its desfuroylceftiofur metabolites in plasma. The addition of cefotaxime as an
internal standard also allows for the correction of intra- and inter-assay variability. This
method has been used successfully to determine ceftiofur concentrations in plasma
samples at this institution.

